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There are major barriers in access to prescription medications for the uninsured,1 
particularly people with chronic conditions, substance abuse, or mental health issues.2,3 In 
2012 uninsured adults were four times more likely than the insured to report not filling a 
prescription due to cost.1 There is some evidence of higher prescription drug use among 
Medicaid enrollees than among the uninsured,4 but isolating the causal effect of the program 
is difficult given that the uninsured differ from people with insurance in many ways that may 
affect care.
We took advantage of a natural experiment in coverage expansion—the Oregon Medicaid 
lottery—to assess the impact of Medicaid on the use of medications. Using a randomized 
controlled design, we found that Medicaid coverage significantly increased the use of 
medications related to the management of several serious conditions (Exhibit 1) and 
substantially reduced the use of medications that were originally prescribed to someone else, 
a key proxy for medication safety.5,6
With the future of Medicaid coverage uncertain, information on how the program affects 
medication use is a critical input for policy makers, patients, and health care providers alike.
Study Data And Methods
The Oregon Health Insurance Experiment
In 2008 Oregon held a lottery for a limited number of slots in its Medicaid expansion 
program, which offered coverage to nondisabled adults with incomes at or below the federal 
poverty level. Oregon drew names randomly from a “reservation list” of nearly 90,000 
people to allocate 10,000 coverage slots; those who were selected received coverage if they 
completed the application process and proved to be eligible based on their income, assets, 
and citizenship status.7 The program was otherwise closed to new enrollment. The program 
offered coverage for a wide range of physical and behavioral health benefits, including 
prescription medications (with no copayment).
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Using the unique opportunity presented by this Medicaid lottery, we conducted a 
randomized controlled evaluation—the Oregon Health Insurance Experiment—that was 
designed to assess the effects on a wide range of health and health care outcomes of 
expanding Medicaid to low-income uninsured adults. In previous analyses, we found that 
Medicaid coverage increased most types of health care utilization, including prescription 
drug use overall.8 Here, for the first time, we explore the way that Medicaid changed 
prescription drug use across the full spectrum of health conditions. We do this via an 
analysis of detailed medication catalogs collected for each participant.
Data
As part of the data collection effort for the Oregon Health Insurance Experiment in 2009–10, 
we conducted detailed in-person interviews and health assessments with people, selected in 
the lottery (the treatment group) and not selected (the control group), approximately two 
years after the lottery for most respondents (for the study flow, see online Appendix Exhibit 
A1; for sample characteristics, see Appendix Exhibit A2).9 Participants were asked to bring 
all of their current medications to these interviews, where study staff members recorded the 
name, dosage, and frequency of each medication directly from the containers. This resulted 
in a sample size of 12,039 (6,293 in the treatment group, 5,746 in the control).
We used data from the resulting catalogs of medications to create several different outcomes. 
First, we categorized medications based on their therapeutic use, using a commercially 
available database to divide medications into mutually exclusive and exhaustive categories 
(for additional details, see Appendix Exhibit A3).9 We report whether respondents possessed 
any medication in each category, as well as the number of medications. Second, we 
categorized medications based on the source of the prescription—that is, whether they were 
prescribed for the respondent or someone else. In supplemental analyses we examined over-
the-counter medications as well as prescription drugs (see Appendix Exhibit 5).9
Analytical Methods
We followed our approach in previous analyses:8,10,11 To assess the impact of Medicaid 
coverage on medication outcomes, we used selection in the lottery as an instrumental 
variable for insurance coverage in two-stage least squares regressions. The first-stage 
regressions showing the effect of lottery selection on Medicaid coverage are shown in 
Appendix Exhibit A4.9 This approach yielded unbiased estimates of the effect of insurance 
coverage on our outcomes of interest (for more detail, see the Appendix text).9 In addition to 
these “local average treatment effects” of Medicaid coverage, Appendix Exhibit A6 reports 
on “intent to treat” estimates of the effect of lottery selection on both prescription 
medications and all medications, including over-the-counter drugs.9 Appendix Exhibit A7 
also shows robustness to different estimation equations (such as logistic regressions).9
Limitations
There were limitations to our approach that should be considered in assessing the 
generalizability of our findings. First, this is a single-state study that reports on data 
collected in 2010. Some states may differ in benefit generosity or may have significantly 
modified their Medicaid programs and pharmacy benefits since that time. Second, our data 
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captured the medications in respondents’ possession at the time of the interview. The 
medications catalogs may be incomplete (although we have no reason to suspect differential 
data quality between the study’s treatment and control arms). More importantly, we do not 
know whether respondents were taking the medications exactly as directed, nor whether they 
had received prescriptions that they had not filled or refilled. Thus, we cannot report directly 
on adherence. Third, we cannot assess the clinical appropriateness of the medications 
possessed by our respondents.
Despite these limitations, this study offers a unique opportunity to assess how Medicaid 
affects the prescription medications that patients actually obtain—a key input in the 
management and treatment of a wide range of health conditions.
Study Results
Overall Medication Use
Medicaid coverage significantly increased both the proportion of individuals with at least 
one prescription medication and the number of prescription medications per person, 
consistent with previous findings.8 Medicaid increased the share of people with at least one 
prescription medication by 11.6 percentage points (relative to the control-group mean of 
49.3 percent) (Exhibit 1) and the number of prescription medications per person by 0.46 
(relative to the control-group mean of 1.56) (Exhibit 2).
Medication Use By Type
Medicaid coverage increased the use of medications related to a number of chronic health 
conditions. The biggest observed increases were in prescription medications for mental 
health (an increase of 0.15 prescription per person), diabetes (0.11), cardiovascular disease 
(0.06), and asthma (0.05) (Exhibit 2). Collectively, these categories were responsible for 80 
percent of the increase seen in the number of medications held by respondents, although 
only the increases for mental health and diabetes were significant. The number of people in 
possession of antibiotics nearly doubled. Changes in other medication categories were small 
in magnitude and insignificant. There was no significant increase in the possession of 
analgesics overall nor of prescription pioids or opioid addiction treatment drugs (often 
referred to as medication-assisted treatment). As noted above, we also tested the impact of 
Medicaid on nonprescription medications (Appendix Exhibit A5).9 The only medication 
category where including over-the-counter drugs substantially changed the estimated effect 
of Medicaid coverage was an increase in the effect for medications for gastrointestinal 
conditions such as ulcers (a condition for which effective over-the-counter medication is 
available and which might be newly diagnosed with increased access to coverage).
Medication Use By Source
Medicaid coverage also influenced the source of prescriptions in respondents’ possession. 
We found that Medicaid increased the number of medications prescribed for the respondents 
themselves by more than 30 percent, while essentially eliminating the possession of 
medications prescribed for someone else (Exhibit 3). The number of medications possessed 
by respondents that were originally prescribed to someone else fell by 0.04 (relative to the 
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control-group mean of 0.03; p = 0.01). Additional details on the regression results displayed 
in Exhibits 1–3 are shown in Exhibit 4.
Discussion
Evidence from this randomized controlled evaluation shows that expanding Medicaid 
coverage to the uninsured drove a substantial increase in the use of prescription medications, 
particularly those that target chronic conditions such as diabetes and mental health. These 
results complement previously released results from the Oregon Health Insurance 
Experiment showing that Medicaid increases the use of primary and preventive care and the 
numbers of emergency department visits and hospital stays.8,10,11
Our study also shows that Medicaid coverage essentially eliminated the use of prescription 
medications that were originally prescribed to someone else. Using someone else’s 
prescribed medications can pose serious safety risks for patients, and this change reveals an 
important additional channel by which coverage can improve health.
There is considerable policy interest in the potential impacts of Medicaid expansion in the 
context of the opioid epidemic. Some policy makers have been concerned that Medicaid 
expansion could increase access to opioids, thereby exacerbating the problem.12 Conversely, 
expanding Medicaid could increase access to medication-assisted treatments for opioid 
addiction.13,14 Our study did not find evidence that Medicaid affected prescriptions for 
either opioids or medication-assisted treatments. However, it is important to note that both 
the extent of the opioid epidemic and the use of the treatments have evolved substantially 
since 2010.13
Overall, our results suggest that Medicaid plays an important role in access to medicines for 
chronic conditions for low-income populations. Chronic physical and behavioral health 
conditions impose a rising health burden on low-income populations, and prescription 
medications are an important tool for managing these conditions. Upstream investments in 
the pharmacological management of chronic illness might lead to fewer costly and invasive 
procedures downstream.15 There may be additional barriers to optimal use and adherence, 
but access to these medications is a necessary first step to their effective use.
In considering policies that expand or contract Medicaid coverage, policy makers should 
consider the subsequent impact on access to prescription medications, particularly for people 
with chronic physical or behavioral health conditions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Exhibit 1. Effect of Medicaid on percentages of people in the Oregon study sample with any 
prescription medication, by type
SOURCE Authors’ analysis of data for 2009–10 from the Oregon Health Insurance 
Experiment. NOTES N = 12,039. Lottery selection was used as an instrument for Medicaid 
coverage in a two-stage least squares estimation. The average value for people not selected 
to receive Medicaid in the lottery (the control group) and the Medicaid effects and 95 
percent confidence intervals (shown by the error bars) were calculated using survey weights. 
The average value for people who received Medicaid through the lottery is the sum of the 
control-group mean and the effect of Medicaid. Medicaid effects were estimated including 
controls for the number of household members on the lottery list and adjusting standard 
errors for household clusters. “Opioids” and “opioid treatment” are mutually exclusive 
subsets of the “pain” category, which also includes medications for pain and inflammation. 
“Asthma” includes medications for asthma and other respiratory medications. “Diabetes” 
includes medications for diabetes and other endocrine medications. “Other” includes 
medications not included in other categories. *p < 0.10 **p < 0.05 ***p < 0.01
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Exhibit 2. Effect of Medicaid on average number of medications in Oregon study participants’ 
possession, by type
SOURCE Authors’ analysis of data for 2009–10 from the Oregon Health Insurance 
Experiment. NOTES Lottery selection was used as an instrument for Medicaid coverage in a 
two-stage least squares estimation. The average value for people not selected to receive 
Medicaid in the lottery (the control group) and the Medicaid effects and 95 percent 
confidence intervals (shown by the error bars) were calculated using survey weights. The 
average value for people who received Medicaid through the lottery is the sum of the control 
group mean and the effect of Medicaid. The sample size, method of estimating Medicaid 
effects, and medication categories are explained in the Notes to Exhibit 1. *p < 0.10 **p < 
0.05
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Exhibit 3. Effect of Medicaid on percentages of people in the Oregon study sample with any 
prescription medication and average number of prescription medications, by recipient of 
prescription
SOURCE Authors’ analysis of data for 2009–10 from the Oregon Health Insurance 
Experiment data. NOTES Lottery selection was used as an instrument for Medicaid 
coverage in a two-stage least squares estimation. The average value for people not selected 
to receive Medicaid in the lottery (the control group) and the Medicaid effects and 95 
percent confidence intervals (shown by the error bars) were calculated using survey weights. 
The average value for people who received Medicaid through the lottery is the sum of the 
control-group mean and the effect of Medicaid. The sample size and method of estimating 
Medicaid effects are explained in the Notes to Exhibit 1. **p < 0.05 ***p < 0.01 ****p < 
0.001
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